Concepedia

Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients

Shumin Yuan, Ling Peng, Yuqing Liu, Brian G. Till, Xiang Yan, Jie Zhang, Liping Zhu, Huijuan Wang, Shaokai Zhang, Hongle Li,

Cancer Immunology Immunotherapy · 2022 · 19 citations · 20 references

DOIFull text

Open access

Concepts

References

20

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text

, , +17

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text

, , +15

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text

, , +17

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

Yuhui Huang, Jian‐Ping Yuan, Elda Righi et al. · Proceedings of the National Academy of Sciences · 2012 · 1.1K citations · Full text

, , +14

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Baohui Han, Kai Li, Qiming Wang et al. · JAMA Oncology · 2018 · 620 citations · Full text

, , +17